Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactis BB-12 + lactobacillus acidophilus LA-5 + lactobacillus plantarum + saccharomyces boulardii
- Development stage
- Unknown
- Lead developer
- Novonesis
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a multi-strain probiotic combination containing Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus plantarum, and Saccharomyces boulardii. These strains are among the most clinically studied probiotics for digestive and immune health.
- Bifidobacterium lactis BB-12 and Lactobacillus acidophilus LA-5 have been shown to help alleviate chronic constipation in elderly patients, reduce symptoms of ulcerative colitis after surgery, improve tolerance to lactose in lactose-intolerant individuals, and reduce the severity of antibiotic-associated diarrhea. They exhibit anti-inflammatory effects by modulating NF-kB signaling pathways and reducing pro-inflammatory cytokines such as TNF-alpha.
- Lactobacillus plantarum is known for its ability to support gut barrier function and modulate immune responses (general knowledge).
- Saccharomyces boulardii is a non-pathogenic yeast widely used for prevention or treatment of antibiotic-associated diarrhea and other gastrointestinal disorders (general knowledge).
The combination acts primarily through modulation of the gut microbiota composition, enhancement of mucosal barrier integrity, competitive exclusion of pathogens, production of beneficial metabolites (such as short-chain fatty acids), immunomodulation via interaction with pattern recognition receptors like TLR2 on intestinal epithelial cells, suppression of inflammatory mediators (e.g., COX-2), reduction in intestinal permeability, and restoration or maintenance of healthy bowel function.
02
Targets
Beyond the preview
Go deeper on bifidobacterium lactis BB-12 + lactobacillus acidophilus LA-5 + lactobacillus plantarum + saccharomyces boulardii.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactis BB-12 + lactobacillus acidophilus LA-5 + lactobacillus plantarum + saccharomyces boulardii.